Delcath FOCUS-Uveal Melanoma

What is the Purpose of this Study?

We are doing this study is to find out if the Melphalan /HDS therapy is effective for people with uveal melanoma that has spread to the liver and to look at side effects of the therapy. We want to find out if the therapy can reduce the size of liver tumors.
What is the Condition Being Studied?
Uveal Melanoma

Who Can Participate in this Study?

Adults with uveal melanoma (started in the eye) that spread to the liver.

Age Group
Participating Institutions

What is Involved?

If you join the study, you will:

- Have a physical exam and other tests

- Imaging scans (CT scans and MRI scans)

- Receive the Melphalan/HDS therapy up to 6 times, once every 6-8 weeks with blood work every week

- Have liver scans every 10-14 weeks.

Study Details

Full Title
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Principal Investigator

Melanoma and other Skin DCI Clinical Research Team
Protocol Number

View on